Related Experiment Video
Updated: Jan 26, 2026

Inducible and Reversible Dominant-negative DN Protein Inhibition
Published on: January 7, 2019
Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism
Andrew B Stergachis1, Jonai Pujol-Giménez2,3, Gergely Gyimesi2,3
1Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Abstract:
SLC1A2 is a trimeric transporter essential for clearing glutamate from neuronal synapses. Recurrent de novo SLC1A2 missense variants cause a severe, early onset developmental and epileptic encephalopathy via an unclear mechanism. We demonstrate that all 3 variants implicated in this condition localize to the trimerization domain of SLC1A2, and that the Leu85Pro variant acts via a dominant negative mechanism to reduce, but not eliminate, wild-type SLC1A2 protein localization and function. Finally, we demonstrate that treatment of a 20-month-old SLC1A2-related epilepsy patient with the SLC1A2-modulating agent ceftriaxone did not result in a significant change in daily spasm count. ANN NEUROL 2019;85:921-926.
Related Concept Videos
Incomplete Dominance
Histone Variants at the Centromere
Negative Regulator Molecules
Positive, Negative, and Zero Work
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...

